Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor N
<p>Breye Therapeutics (Breye), a Danish clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases, has closed an oversubscribed €67.5 million Series A financing round. The round was co-led by new investor Mission BioCapital and existing investor N</p>